Abstract
Objective:
To determine predictive factors influencing visual acuity (VA) recovery, optical coherence tomography (OCT) metrics and visual field (VF) parameters in inaugural optic neuritis (ON) of Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) patients.
Methods:
In this retrospective study, we collected orbital MRI, ophthalmological evaluations (VA, OCT, VF), and acute treatment data. MRI assessed enhancement intensity, longitudinal extent, anatomical involvement, optic perineuritis and optic nerve head edema. Ophthalmological parameters included VA, VF mean deviation (MD), peripapillary retinal nerve fiber layer (pRNFL) thickness and macular ganglion cell-inner plexiform layer (mGCIPL) volume. Prognostic factors were assessed using regression analysis.
Results:
We included 78 patients with inaugural MOGAD-ON. Complete VA recovery (logMAR ⩽ 0) was achieved in 69 patients (88.5%). In multivariate analysis, high-dose intravenous methylprednisolone treatment delay was the only significant prognostic factor for final VA (β = 0.36, p = 0.002) and VF MD (β = −0.31, p = 0.037). In multivariate analysis, worse nadir VA predicted thinner final pRNFL (β = −0.40, p = 0.003), while both longer MRI optic nerve lesion length (β = −0.31, p = 0.021) and poorer nadir VA (β = −0.45, p = 0.001) were significantly associated with reduced final mGCIPL volumes.
Conclusion:
We found distinct prognostic factors between visual impairment and structural damage in MOGAD-ON, underscoring the need for prompt diagnosis and acute treatment.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
